References
[1] Ingle SB, Hinge Ingle CR. Eosinophilic gastroenteritis: An unusual type of gastroenteritis. World J Gastroenterol. 2013; 19:5
[2] Heikh RA, Prindiville TP, Pecha RE, Ruebner BH. Unusual presentations of eosinophilic gastroenteritis: case series and review of literature. World J Gastroenterol. 2009; 15(17):2156-2161.
[3] Klein NC, Hargrove RL, Sleisenger MH, Jeffries GH. Eosinophilic gastroenteritis. Medicine (Baltimore). 1970; 49(4):299-319.
[4] Rothenberg ME, Hottinger SKB, Gonsalves N, Furuta GT, Collins MH, Talley NJ, et al. Impressions and aspirations from the FDA GREAT VI workshop on eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis and perspectives for progress in the field. J Allergy Clin Immunol. 2022; 149:844-853.
[5] Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE. Eosinophilic gastroenteritis: clinical experience with 15 patients. World Gastroenterol. 2003; 9(12):2813-2816.
[6] Tian XQ, Chen X, Chen SL. Eosinophilic gastroenteritis with abdominal pain and ascites: a case report. World J Clin Cases. 2021, 9(17): 4238-4243.
[7] Sunkara T, Rawla P, Yarlagadda KS, Gaduputi V. Eosinophilic gastroenteritis: diagnosis and clinical perspectives. Clin Exp Gastroenterol. 2019; 12:239-53.
[8] Egan M, Furuta GT. Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018; 121: 162-167.
[9] Katz A.J., Twarog F.J., Zeiger R.S., Falchuk Z.M. Milk-sensitive and eosinophilic gastroenteropathy: similar clinical features with contrasting mechanisms and clinical course. J. Allergy Clin. Immunol. 1984, 74 (1) : 72-78.
[10] Chang JY, Choung RS, Lee RM, Locke GR, Schleck CD, Zinsmeister AR, et al. A shift in the clinical spectrum of eosino-philic gastroenteritis toward the mucosal disease type. Clin Gastroenterol Hepatol. 2010;8(8):669-75.
[11] Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: Effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009; 9:32.
[12] Netzer P, Gschossmann JM, Straumann A, Sendensky A, Weimann R, Schoepfer AM. Corticosteroid-dependent eosinophilic oesophagitis: Azathioprine and 6-mercaptopurine can induce and maintain longterm remission. Eur J Gastroenterol Hepatol. 2007; 19:865-869.
[13] Kandikattu HK, Venkateshaiah SU, Verma AK, Mishra A. Tacrolimus (FK506) treatment protects allergen- , IL-5- and IL-13- induced mucosal eosinophilia. Immunology. 2021; 163:220-235.
[14] Benjamin MR, Bochner BS, Peters AT. Mepolizumab use: Postapproval academic practice experience. Ann Allergy Asthma Immunol. 2018; 121:126-128.
[15] Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: A randomised, placebocontrolled, double-blind trial. Gut. 2010; 59:21-30.
[16] Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007; 120:594-601.
[17] Pinte L, Băicus C. Eosinophilic pancreatitis versus pancreatitis associated with eosinophilic gastroenteritis-A systematic review regarding clinical features and diagnosis. Rom J Intern Med. 2019; 57:284-295.
[18] Sunkara T, Rawla P, Yarlagadda KS, Gaduputi V. Eosinophilic gastroenteritis: Diagnosis and clinical perspectives. Clin Exp Gastroenterol. 2019; 12:239-253.